The Employer GLP-1 Coverage Squeeze: Pullbacks Continue While Lilly Lobbies to Expand — "Coverage Is the Main Constraint, Not Demand"

The Employer GLP-1 Coverage Squeeze: Pullbacks Continue While Lilly Lobbies to Expand — "Coverage Is the Main Constraint, Not Demand"

The battle over who pays for GLP-1s is sharpening into a two-sided fight: employers and payers are engineering ways to cap exposure, while manufacturers — chiefly Eli Lilly — are lobbying to keep doors open.

The pullback side:

• Employer health benefits consultants project employer healthcare costs will rise 9.5% in 2027, with "high utilization and claim costs, chronic conditions and the growing use of GLP-1 therapies" continuing to drive spending pressure (Healthcare Finance News).
• A USA Today consumer guide (Sep 15, 2026) notes that in 2025 "only 43% of the largest U.S. employers, and 16% of mid-size firms, covered GLP-1s for weight loss¹" — and compounded-GLP-1 providers are marketing to the resulting cash-pay gap under "tightening regulatory pressure."
• The Washington Post's Sep 16 health brief frames the fight directly: "Eli Lilly is trying to increase health insurance coverage of GLP-1s, even as some employers are pulling back."
• PBM/product responses are proliferating: Navitus launched "GLP-1 Pathways and DirectAccess" (Sep 15, 2026) — "as employers and other plan sponsors grapple with rising demand for GLP-1 medications and the financial challenges" — channeling members into structured, lower-cost GLP-1 access rather than open-ended coverage.

The manufacturer counter-offensive. At the Morgan Stanley Global Healthcare Conference (September 2026), Lilly executives were explicit about where the bottleneck sits: "We have seen some employers recently remove coverage. We are also in discussions with many employers on adding coverage." Their toolkit is the Employer Connect program — "conversations with a lot of employers about the different options, whether it is PBM or Employer Connect program, to add coverage and flexibility in the employee cost sharing" — plus health-economic evidence generation and possible Medicaid expansion in more states. The key strategic admission: "coverage remains the main constraint, not demand."²

Investor takeaway: demand is not the limiting variable — payer willingness is. That inverts the bull case risk: script growth from here depends on coverage decisions (employers for commercial lives, CMS for seniors via the Bridge, see Medicare GLP-1 Bridge Hits 700K Seniors; Lilly Captures 70% at $245/Month Net — "Very Market-Expansionary"), not on patient appetite. The employer-retrenchment trend (see The Employer GLP-1 Coverage Squeeze: Pullbacks Continue While Lilly Lobbies to Expand — "Coverage Is the Main Constraint, Not Demand" for the Cigna/TruRx precedent) is a persistent headwind Lilly is trying to offset with Employer Connect-style cost-sharing flexibility, while Novo leans on cash-pay channels (NovoCare) and the Wegovy pill's price point. Watch 2027 plan-year benefit design announcements this fall for the next read on employer appetite.